Cargando…
Correction to: Amyloid PET, FDG-PET or MRI? - the power of different imaging biomarkers to detect progression of early Alzheimer’s disease
Autores principales: | Ortner, Marion, Drost, René, Hedderich, Dennis, Goldhardt, Oliver, Müller-Sarnowski, Felix, Diehl-Schmid, Janine, Förstl, Hans, Yakushev, Igor, Grimmer, Timo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057451/ https://www.ncbi.nlm.nih.gov/pubmed/32138693 http://dx.doi.org/10.1186/s12883-020-01649-9 |
Ejemplares similares
-
Amyloid PET, FDG-PET or MRI? - the power of different imaging biomarkers to detect progression of early Alzheimer’s disease
por: Ortner, Marion, et al.
Publicado: (2019) -
Regional Cerebral Associations Between Psychometric Tests and Imaging Biomarkers in Alzheimer’s Disease
por: Hedderich, Dennis M., et al.
Publicado: (2020) -
The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort
por: Amft, Michaela, et al.
Publicado: (2022) -
Elecsys Cerebrospinal Fluid Immunoassays Accurately Detect Alzheimer’s Disease Regardless of Concomitant Small Vessel Disease
por: Ortner, Marion, et al.
Publicado: (2023) -
Kallikrein-related peptidases 6 and 10 are elevated in cerebrospinal fluid of patients with Alzheimer’s disease and associated with CSF-TAU and FDG-PET
por: Goldhardt, Oliver, et al.
Publicado: (2019)